Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of growth differentiation factor 11 in promoting healing diabetic wound

A growth differentiation factor, wound healing technology, applied in the field of medicine, can solve the problems of difficult healing of diabetic wounds, infection gangrene, vascular granulation, epithelial formation and remodeling and other problems that the healing process cannot be completed.

Active Publication Date: 2016-07-20
HARBIN MEDICAL UNIVERSITY
View PDF2 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Due to the lack of signaling molecules that mediate wound healing in diabetic cells or tissues and the low immunity caused by high blood sugar, the healing process such as angiogenesis, granulation, epithelial formation and reconstruction cannot be completed, making it difficult for diabetic wounds to heal
If aggressive treatment does not adequately address the symptoms and complications that develop in the lower extremities, it can have disastrous consequences, including infected gangrene or amputation, greatly reducing the patient's quality of life

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of growth differentiation factor 11 in promoting healing diabetic wound
  • Use of growth differentiation factor 11 in promoting healing diabetic wound
  • Use of growth differentiation factor 11 in promoting healing diabetic wound

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0030] The establishment of embodiment 1 mouse diabetes model

[0031] Get 60 mice, fast without water for 12h, inject STZ solution (10mg / ml) intraperitoneally by 1.8mg (STZ) / 10g mouse body weight, then give 5% glucose water for 12h, and resume normal eating the next day. water. After 7 days, the postprandial blood glucose value was measured, and the mice with blood glucose concentration higher than 16.7mmol / L were regarded as diabetic mice (DM), that is, the modeling was successful. figure 1 shown.

Embodiment 2

[0032] Example 2 Establishment of Mouse Diabetic Wound Model

[0033] Take 30 diabetic model mice and 10 normal mice, inject Avertin solution (0.02g / ml) intraperitoneally according to the standard of 0.10ml / 10g mouse body weight, carry out anesthesia, remove the hair on the back to expose the skin, and use a skin puncher , A circular full-thickness skin wound with a diameter of 5 mm was made on the lower 1 / 3 of the back of the mouse (including the subcutaneous tissue of the epidermis and dermis. It is better to see the subcutaneous muscles and bones after punching and cutting off the skin). Each mouse was housed in a single cage.

Embodiment 3

[0034] Example 3 Grouping and Administration of Diabetic Wound Model Mice

[0035]Thirty diabetic wound model mice were randomly divided into 4 groups: (1) blank control group (DM): 0.1% BSA buffer was added to the wound; (2) positive control group (EGF+DM): the wound was dripped with 50ng / ml epidermal growth factor (EGF) solution; (3) Experimental group (GDF-11+DM): 50ng / ml GDF-11 solution was added to the wound; in addition, non-diabetic normal wound model mice (10) were used as negative controls Group (ctl), wherein the amino acid sequence of GDF-11 (purchased from Peprotech company) is as Figure 5 shown.

[0036] Dosing method: The administration frequency of the positive control group, the experimental group, the blank control group and the negative control group is to administer twice a day for each wound, and the administration time point is fixed, and the total volume of each administration is 10ul. The way of medicine is smearing, and the formulations of the medici...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses use of growth differentiation factor 11 in promoting healing of a diabetic wound and belongs to the technical field of medicine. By establishing a Type-I diabetic mouse wound model induced with streptozotocin (STZ) of effective concentration, the influence of the growth differentiation factor 11 upon the healing of the diabetic mouse wound model is estimated, the study discovers that the growth differentiation factor 11 can accelerate the healing of the diabetic mouse wound, and the healing speed of the wound is higher than that of both a positive control group (EGF) and a blank control group. Therefore, an effective technical means to heal and treat diabetic wounds is provided herein.

Description

technical field [0001] The present invention relates to the new application of growth differentiation factor-11 (GDF-11), in particular to the application of growth differentiation factor-11 (GDF-11) in promoting diabetic wound healing. The invention belongs to the technical field of medicine. Background technique [0002] With the improvement of living standards, population aging and lifestyle changes, and the advancement of diagnostic technology, the incidence of diabetes is increasing year by year, and it is expected to reach 300 million people by 2025, becoming the third largest after cardiovascular and malignant tumors. Non-communicable diseases seriously endanger human health and social development. About 30% to 80% of diabetic patients have skin lesions, also known as diabetic feet, which mainly manifest as tissue destruction of the feet or lower limbs, resulting in refractory ulcerative wounds. The pathogenesis of diabetic wound healing is mainly closely related to...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/18A61P17/02A61P3/10
CPCA61K38/1841
Inventor 杨宝峰王志国吕延杰张莹孙丽华
Owner HARBIN MEDICAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com